Lung Cancer Serum

Lung Cancer Serum for Thoracic Oncology and Biomarker Research

Our Lung Cancer Serum is sourced from IRB-consented donors clinically diagnosed with lung cancer, with each sample processed and frozen within 24 hours of collection. Lung cancer is a neoplastic disease with two clinically distinct branches — non-small cell lung cancer, dominated by adenocarcinoma and squamous cell carcinoma, and small cell lung cancer, a neuroendocrine malignancy with very different behaviour. Serum supports the circulating protein and antibody side of research across both.

Why Serum for Lung Cancer

Most lung cancer is diagnosed at an advanced stage, which is why blood-based detection, prognostication and monitoring remain such active research areas. Serum is the established matrix for the protein tumour markers and serological approaches in that effort, and the histology-specific behaviour of those markers is one of the most useful facts in the field.

• Serum tumour markers are histology-dependent — CYFRA 21-1 and squamous cell carcinoma antigen associate with squamous histology, CEA with adenocarcinoma, while neuron-specific enolase and pro-gastrin-releasing peptide are the established circulating markers of small cell lung cancer. Histology-annotated serum is therefore essential rather than optional.
• Tumour-associated autoantibody panels — the humoral response to tumour antigens can precede radiographic detection, and serum autoantibody panels have been developed commercially for lung nodule risk stratification. Serum, not plasma, is the correct matrix for this work.
• Immunotherapy era readouts — checkpoint blockade is now standard across much of advanced lung cancer, and serum supports research on soluble PD-L1, cytokine correlates of response, and immune-related toxicity signatures.
• Systemic inflammation and cachexia — IL-6, CRP and albumin-based prognostic indices carry independent prognostic information in lung cancer and are measurable alongside tumour markers from the same aliquot.
• Cleaner immunoassay background — clot formation removes fibrinogen and much of the coagulation cascade, reducing matrix interference in high-sensitivity protein immunoassays relative to plasma.
• Complementary to plasma — for liquid-biopsy genotyping of EGFR, ALK, KRAS and resistance mutations, EDTA plasma is the appropriate matrix; use serum for proteins and antibodies and pair with the plasma sibling for ctDNA.

Donor Stratification Available

• Histology: adenocarcinoma, squamous cell carcinoma, other non-small cell histology, or small cell lung cancer
• Stage at collection and TNM classification where recorded; limited versus extensive stage for small cell disease
• Driver alteration status (EGFR, ALK, ROS1, KRAS and others) where reported in the clinical record
• PD-L1 expression status where reported
• Treatment status: treatment-naive, targeted tyrosine kinase inhibitor, platinum chemotherapy, checkpoint inhibitor, or post-resection
• Smoking history and pack-year exposure where recorded
• Matched healthy controls available, age-, sex- and smoking-status-matched on request

Product Features

• Collected from clinically confirmed lung cancer donors
• Processed and frozen within 24 hours of collection
• Custom aliquot volumes available; volumes reported per lot
• Research Use Only (RUO)
• IRB-approved protocols with documented consent

De-identified Donor Data

• Diagnosis confirmation, including histology where available
• Age, sex assigned at birth, and race/ethnicity
• Donor-reported allergy, medication and infectious disease history
• Stage, molecular status, PD-L1 status and treatment history where reported

Applications

• Biomarker discovery and validation for lung cancer detection, prognosis and monitoring
• Histology-stratified serum tumour marker panel development
• Tumour-associated autoantibody panel discovery and validation
• Serum cytokine and multiplex protein profiling in immunotherapy cohorts
• Soluble immune checkpoint protein research
• Systemic inflammation, cachexia and prognostic index research
• Quantitative serum proteomics and mass spectrometry method development
• Assay qualification and reference material for thoracic oncology programmes

Other Lung Cancer Specimen Types

• Lung Cancer Plasma — for ctDNA and liquid-biopsy genotyping
• Lung Cancer Whole Blood
• Lung Cancer PBMC
• Lung Cancer Leukopak
• Non-Small Cell Lung Cancer Serum for histology-specific cohorts
• Lung Adenocarcinoma Whole Blood

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Lung cancer serum is available in standard and custom volumes. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international orders or documentation requirements to ensure compatibility with your country’s regulations. To browse availability across all disease states, visit our human serum page.